IMab (IMAB)
(Delayed Data from NSDQ)
$1.08 USD
-0.03 (-2.70%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $1.08 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth B Momentum F VGM
Income Statements
Fiscal Year end for IMab Sponsored ADR falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 4 | -32 | 14 | 236 | 4 |
Cost Of Goods | 0 | 4 | 7 | 0 | 0 |
Gross Profit | 4 | -36 | 7 | 236 | 4 |
Selling & Adminstrative & Depr. & Amort Expenses | 178 | 249 | 332 | 213 | 215 |
Income After Depreciation & Amortization | -174 | -286 | -325 | 24 | -210 |
Non-Operating Income | -32 | -78 | -41 | 50 | 2 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -206 | -363 | -366 | 74 | -209 |
Income Taxes | 0 | 0 | -1 | 2 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -206 | -364 | -366 | 72 | -209 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -206 | -364 | -366 | 72 | -209 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -167 | -276 | -320 | 27 | -208 |
Depreciation & Amortization (Cash Flow) | 7 | 9 | 5 | 4 | 2 |
Income After Depreciation & Amortization | -174 | -286 | -325 | 24 | -210 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 88.60 | 82.52 | 75.96 | 68.36 | 7.38 |
Diluted EPS Before Non-Recurring Items | -2.07 | -4.24 | -4.82 | 1.06 | -28.90 |
Diluted Net EPS (GAAP) | -2.48 | -4.41 | -4.82 | 1.06 | -66.47 |
Fiscal Year end for IMab Sponsored ADR falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 0.00 | NA | NA | NA | NA |
Cost Of Goods | 0.00 | NA | NA | NA | NA |
Gross Profit | 0.00 | NA | NA | NA | NA |
SG&A, R&D, and Dept/Amort Expenses | 15.01 | 0.00 | 0.00 | 0.00 | 0.00 |
Income After SG&A, R&D, and Dept/Amort Expenses | -15.01 | 0.00 | 0.00 | 0.00 | 0.00 |
Non-Operating Income | 8.20 | NA | NA | NA | NA |
Interest Expense | 0.00 | NA | NA | NA | NA |
Pretax Income | -6.81 | NA | NA | NA | NA |
Income Taxes | 0.00 | NA | NA | NA | NA |
Minority Interest | 0.00 | NA | NA | NA | NA |
Investment Gains/Losses | 0.00 | NA | NA | NA | NA |
Other Income/Charges | 0.00 | NA | NA | NA | NA |
Income From Cont. Operations | -6.81 | NA | NA | NA | NA |
Extras & Discontinued Operations | 31.94 | NA | NA | NA | NA |
Net Income (GAAP) | 25.13 | NA | NA | NA | NA |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 80.93 | NA | NA | NA | NA |
Diluted EPS Before Non-Recurring Items | -0.07 | NA | NA | NA | NA |
Diluted Net EPS (GAAP) | 0.30 | NA | NA | NA | NA |